Re: 'A single zoleledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density' by Saag et al.
Lee
Jong In
JI
Kim
Hye Won
HW
D000284:Administration, Oral; D019386:Alendronate / Q000008:administration & dosage* / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000097:blood* / Q000517:prevention & control*; D004164:Diphosphonates / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D007275:Injections, Intravenous; D013997:Time Factors; D000077211:Zoledronic Acid
D015415:Biomarkers; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D019386:Alendronate